BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30
• 31

• 

  Obesity

  Obesity-Focused Aardvark Therapeutics Files IPO to Advance Lead Candidate

  The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

  January 24, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Obesity

  Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss

  The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% weight reduction.

  January 24, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Phase III

  Merck’s Keytruda Combo Fails to Extend Survival in Phase III GI Cancer

  The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against its limits after racking up around 50 approvals since getting its first FDA nod in September 2014.

  January 24, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Editorial

  Trump’s First Week: A Binge-Worthy Show, If Nothing Else

  Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health agencies, among other moves that have sent waves through the biopharma industry.

  January 24, 2025

   · 

  4 min read

   · 

  Jef Akst
• 

  Legal

  Purdue Pharma, Sacklers Settle Opioid Lawsuits For $7.4B

  The settlement is the largest deal to date with the people primarily who played an “instrumental role” in driving the opioid crisis, according to the office of Massachusetts Attorney General Andrea Joy Campbell.

  January 24, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Government

  Senate Lines Up RFK Jr. Confirmation Hearing Amid Mounting Criticism

  Robert F. Kennedy, Jr.’s recent disclosures have revealed several potential conflicts of interest, including investments in two biopharma companies.

  January 24, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

  January 24, 2025

   · 

  20 min read
• Press Releases

  Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  January 24, 2025

   · 

  1 min read
• Press Releases

  Moss Genomics Provides Corporate Update and Announces Shift in Business Strategy

  January 24, 2025

   · 

  8 min read
• Press Releases

  ImmunoMet Therapeutics Presents Updated Clinical Data from Phase 1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting

  January 24, 2025

   · 

  3 min read